FMR LLC and Abigail P. Johnson filed a Schedule 13G with the SEC on November 5, 2026, disclosing beneficial ownership of 667,465 shares of Gossamer Bio Inc. common stock as of October 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: FMR LLC and Abigail P. Johnson each reported beneficial ownership of 667,465 shares of Gossamer Bio Inc. common stock.
  • Percent of class: The 667,465 shares represent 10.9% of the total outstanding common stock, according to the filing.
  • Sole dispositive power: Both FMR LLC and Abigail P. Johnson each reported sole dispositive power over 667,465 shares, with no shared dispositive power.
  • Sole voting power: FMR LLC reported sole voting power over 667,460 shares; Abigail P. Johnson reported sole voting power of 0 shares.
  • Select Biotechnology Portfolio: The filing disclosed that Select Biotechnology Portfolio holds an interest of 667,460 shares, representing 10.9% of total outstanding common stock.
  • Triggering event date: The date of the event requiring this filing was October 30, 2026.

FMR LLC and Abigail P. Johnson Disclose 10.9% Position in Gossamer Bio

FMR LLC, a Delaware-organized holding company with its principal business office at 245 Summer Street, Boston, Massachusetts 02210, filed a Schedule 13G disclosing a 10.9% beneficial ownership position in Gossamer Bio Inc. (CUSIP 38341P201). The filing was signed on November 5, 2026, by Stephanie J. Brown, acting under a power of attorney on behalf of FMR LLC. Abigail P. Johnson, a United States citizen, was also named as a reporting person in the same filing, with the same aggregate beneficial ownership of 667,465 shares and 10.9% of the class.

According to the filing, FMR LLC holds sole voting power over 667,460 shares and sole dispositive power over 667,465 shares, with no shared voting or dispositive power reported. Abigail P. Johnson reported sole dispositive power over 667,465 shares, but no sole or shared voting power. The filing identified FMR LLC as a parent holding company or control person under Rule 13d-1(b)(1)(ii)(G).

The filing further disclosed that Select Biotechnology Portfolio is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the common stock of Gossamer Bio Inc., with an interest amounting to 667,460 shares, or 10.9% of total outstanding common stock as of October 30, 2026. The filers certified that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

FMR LLC and Abigail P. Johnson disclosed aggregate beneficial ownership of 667,465 shares of Gossamer Bio Inc. common stock, equal to 10.9% of the class, as of October 30, 2026, via a Schedule 13G filed November 5, 2026.